Literature DB >> 20596866

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

Irene Virgolini1, Valentina Ambrosini, Jamshed B Bomanji, Richard P Baum, Stefano Fanti, Michael Gabriel, Nikolaos D Papathanasiou, Giovanna Pepe, Wim Oyen, Clemens De Cristoforo, Arturo Chiti.   

Abstract

The aim of these guidelines is to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin (SST) receptor PET/CT imaging using 68Ga-DOTA-conjugated peptides, analogues of octreotide, that bind to SST receptors. This imaging modality should not be regarded as the only approach to visualizing tumours expressing SST receptors or as excluding other imaging modalities useful for obtaining comparable results. The corresponding guidelines of 111In-pentetreotide scintigraphy imaging have been considered and partially integrated with this text. The same has been done with the relevant and recent literature in this field and the final result has been discussed by distinguished experts.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20596866     DOI: 10.1007/s00259-010-1512-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  44 in total

1.  Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.

Authors:  H R Balon; S J Goldsmith; B A Siegel; E B Silberstein; E P Krenning; O Lang; K J Donohoe
Journal:  J Nucl Med       Date:  2001-07       Impact factor: 10.057

2.  Radiolabelling DOTA-peptides with 68Ga.

Authors:  Wouter A P Breeman; Marion de Jong; Erik de Blois; Bert F Bernard; Mark Konijnenberg; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-18       Impact factor: 9.236

3.  Radiolabelling, quality control and radiochemical purity assessment of the Octreotide analogue 68Ga DOTA NOC.

Authors:  D Di Pierro; A Rizzello; G Cicoria; F Lodi; M Marengo; D Pancaldi; S Trespidi; S Boschi
Journal:  Appl Radiat Isot       Date:  2007-12-08       Impact factor: 1.513

4.  111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Valentina Ambrosini; Cumali Aktolun; Richard P Baum; Angelica Bishof-Delaloye; Silvana Del Vecchio; Lorenzo Maffioli; Luc Mortelmans; Wim Oyen; Giovanna Pepe; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07       Impact factor: 9.236

Review 5.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

6.  Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.

Authors:  Stefano Fanti; Valentina Ambrosini; Paola Tomassetti; Paolo Castellucci; Giancarlo Montini; Vincenzo Allegri; Gaia Grassetto; Domenico Rubello; Cristina Nanni; Roberto Franchi
Journal:  Biomed Pharmacother       Date:  2008-03-03       Impact factor: 6.529

7.  Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

Authors:  Daniel Putzer; Michael Gabriel; Benjamin Henninger; Dorota Kendler; Christian Uprimny; Georg Dobrozemsky; Clemens Decristoforo; Reto Josef Bale; Werner Jaschke; Irene Johanna Virgolini
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

8.  A fully automated synthesis for the preparation of 68Ga-labelled peptides.

Authors:  Clemens Decristoforo; Roger Knopp; Elisabeth von Guggenberg; Marco Rupprich; Thorsten Dreger; Andre Hess; Irene Virgolini; Roland Haubner
Journal:  Nucl Med Commun       Date:  2007-11       Impact factor: 1.690

9.  Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.

Authors:  A Chiti; S Fanti; G Savelli; A Romeo; B Bellanova; M Rodari; B J van Graafeiland; N Monetti; E Bombardieri
Journal:  Eur J Nucl Med       Date:  1998-10

10.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

Authors:  I Buchmann; M Henze; S Engelbrecht; M Eisenhut; A Runz; M Schäfer; T Schilling; S Haufe; T Herrmann; U Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-23       Impact factor: 9.236

View more
  121 in total

Review 1.  ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.

Authors:  Valentina Ambrosini; Davide Campana; Paola Tomassetti; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

2.  Recommended administered activities for (68)Ga-labelled peptides in paediatric nuclear medicine.

Authors:  J Soares Machado; S Beykan; K Herrmann; M Lassmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-09       Impact factor: 9.236

Review 3.  SPECT/CT and tumour imaging.

Authors:  Gad Abikhzer; Zohar Keidar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-29       Impact factor: 9.236

4.  Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy.

Authors:  L de la Cueva; P Lloro; M J Sangrós; L López Vélez; P Navarro; L Sarria; S Álvarez; D Abós
Journal:  Clin Transl Oncol       Date:  2017-01-31       Impact factor: 3.405

5.  Impact of Tumor Burden on Quantitative [68Ga] DOTATOC Biodistribution.

Authors:  Rudolf A Werner; Heribert Hänscheid; Jeffrey P Leal; Mehrbod S Javadi; Takahiro Higuchi; Martin A Lodge; Andreas K Buck; Martin G Pomper; Constantin Lapa; Steven P Rowe
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

6.  Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomography.

Authors:  Constantin Lapa; Rudolf A Werner; Ken Herrmann
Journal:  Endocrine       Date:  2015-06-18       Impact factor: 3.633

Review 7.  Neuroendocrine tumours: the role of imaging for diagnosis and therapy.

Authors:  Martijn van Essen; Anders Sundin; Eric P Krenning; Dik J Kwekkeboom
Journal:  Nat Rev Endocrinol       Date:  2013-12-10       Impact factor: 43.330

8.  Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient.

Authors:  Manuel Weber; Lukas Kessler; Benedikt Schaarschmidt; Wolfgang Peter Fendler; Harald Lahner; Gerald Antoch; Lale Umutlu; Ken Herrmann; Christoph Rischpler
Journal:  BMC Cancer       Date:  2020-04-16       Impact factor: 4.430

9.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Authors:  L Bodei; J Mueller-Brand; R P Baum; M E Pavel; D Hörsch; M S O'Dorisio; T M O'Dorisio; T M O'Dorisiol; J R Howe; M Cremonesi; D J Kwekkeboom; John J Zaknun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05       Impact factor: 9.236

10.  Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.

Authors:  Yusuf Menda; Laura L Boles Ponto; Michael K Schultz; Gideon K D Zamba; G Leonard Watkins; David L Bushnell; Mark T Madsen; John J Sunderland; Michael M Graham; Thomas M O'Dorisio; M Sue O'Dorisio
Journal:  Pancreas       Date:  2013-08       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.